Page last updated: 2024-11-07

npf-etoposide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

NPF-etoposide: RN given refers to (5R-(5alpha,5abeta,8aalpha,9beta))-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122849
CHEMBL ID281692
SCHEMBL ID13439902
MeSH IDM0231039

Synonyms (15)

Synonym
nsc628679
1,3-dioxol-6(5h)- one der.
(5s,5as,8ar,9r)-5-(4-fluoroanilino)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5h-isobenzofuro[5,6-f][1,3]benzodioxol-8-one
125830-36-6
(5ar,9s)-9-[(4-fluorophenyl)amino]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
CHEMBL281692
(5s,5as,8ar,9r)-5-(4-fluoroanilino)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
npf-etoposide
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 9-((4-fluorophenyl)amino)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5r-(5alpha,5abeta,8abeta,9beta))-
9-((4-fluorophenyl)amino)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, (5r-(5alpha,5abeta,8aalpha,9beta))-
nsc 628679
(5r-(5alpha,5abeta,8aalpha,9beta))-9-((4-fluorophenyl)amino)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one
4'-o-demethyl-4-(4''-fluoroanilino)-4-desoxypodophyllotoxin
SCHEMBL13439902
DTXSID20154953
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 2-alphaHomo sapiens (human)ID5011.25005.00007.500010.0000AID211300; AID335667; AID399597; AID53301; AID57200; AID57201; AID57204; AID57205
DNA topoisomerase 2-betaHomo sapiens (human)ID505.83335.00007.500010.0000AID211300; AID53301; AID57200; AID57201; AID57204; AID57205
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID92115Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from leukemia in test 9; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID92107Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from small cell lung cancer in test 3; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID492487Cytotoxicity against human vincristine-resistant KB cells after 72 hrs by MTT assay2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID52060Effect on cellular protein DNA complex formation(%) at 10 uM in comparison with etoposide1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antitumor agents. 123. Synthesis and human DNA topoisomerase II inhibitory activity of 2'-chloro derivatives of etoposide and 4 beta-(arylamino)-4'-O-demethylpodophyllotoxins.
AID399596Inhibition of human DNA topoisomerase 2 assessed as DNA cleavage at 20 uM2004Journal of natural products, Feb, Volume: 67, Issue:2
Current developments in the discovery and design of new drug candidates from plant natural product leads.
AID335667Inhibition of human DNA topoisomerase 21992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 130, Novel 4 beta-arylamino derivatives of 3',4'-didemethoxy-3',4'-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID91970Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from colon cancer in test 4; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID399597Inhibition of human DNA topoisomerase 22004Journal of natural products, Feb, Volume: 67, Issue:2
Current developments in the discovery and design of new drug candidates from plant natural product leads.
AID96350Concentration required for 50% reduction in KB cell number after 3-day incubation1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antitumor agents. 123. Synthesis and human DNA topoisomerase II inhibitory activity of 2'-chloro derivatives of etoposide and 4 beta-(arylamino)-4'-O-demethylpodophyllotoxins.
AID92114Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from leukemia in test 1; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID91976Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from CNS cancer in test 5; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID91968Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from Melanoma in test 6; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID91979Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from Renal cancer in test 8; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID57205Inhibitory activity against human DNA topoisomerase II1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
AID221633Cellular protein-DNA complex formation at 10 uM.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID57204Inhibition of human DNA topoisomerase II1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID92117Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from small-cell-lung cancer in test 3; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID335666Cytotoxicity against human KB cells assessed as reduction in cell number after 3 days1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 130, Novel 4 beta-arylamino derivatives of 3',4'-didemethoxy-3',4'-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID91971Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from leukemia in test 9; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID53302Inhibition of DNA topoisomerase II at 100 uM.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID92110Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from Melanoma in test 6; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID492485Cytotoxicity against human KB1 cells after 72 hrs by MTT assay2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID94175Cytotoxicity against KB-ATCC cell lines after a 3-day incubation1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Antitumor agents. 144. New gamma-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II.
AID211458Compound tested for ability to form a cellular covalent topoisomerase II-DNA complex.1996Journal of medicinal chemistry, Mar-29, Volume: 39, Issue:7
Antitumor agents. 163. Three-dimensional quantitative structure-activity relationship study of 4'-O-demethylepipodophyllotoxin analogs using the modified CoMFA/q2-GRS approach.
AID52064Inhibition of cellular protein-DNA complex formation at 10 uM1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
AID91969Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from Ovarian cancer in test 7; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID80116Inhibitory activity against human cytomegalovirus (HCMV)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID91967Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from CNS cancer in test 5; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID92105Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from leukemia in test 1; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID93836GI values against KB cells (nasopharyngeal carcinoma)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID492486Cytotoxicity against human KB-7d cells after 72 hrs by MTT assay2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID42742GI values against CAKI-1 cells(renal carcinoma)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID92116Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from ovarian cancer in test 7; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID53303Percent of cellular protein-DNA complex formation at concentration of 20 uM1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Antitumor agents. 144. New gamma-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II.
AID9244GI values against A549 cells (lung cancer)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID92104Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from colon cancer in test 4; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID96389Concentration for 50% reduction in cell number after 3-day incubation1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Antitumor agents. 113. New 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
AID492484Cytotoxicity against human KB cells after 72 hrs by MTT assay2010Journal of natural products, Mar-26, Volume: 73, Issue:3
Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID211300Inhibition of human DNA topoisomerase II activity1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Antitumor agents. 144. New gamma-lactone ring-modified arylamino etoposide analogs as inhibitors of human DNA topoisomerase II.
AID92109Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from CNS cancer in test 5; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID335669Inhibition of strand rejoining activity of human DNA topoisomerase 2 assessed as protein-DNA complex formation at 10 uM by cell-based assay1992Journal of natural products, Aug, Volume: 55, Issue:8
Antitumor agents, 130, Novel 4 beta-arylamino derivatives of 3',4'-didemethoxy-3',4'-dioxo-4-deoxypodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID91977Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from Non small cell lung cancer in test 2; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID92111Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from Non small cell lung cancer in test 2; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID52061Effect on cellular protein DNA complex formation(%) at 10 uM in comparison with etoposide1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antitumor agents. 124. New 4 beta-substituted aniline derivatives of 6,7-O,O-demethylene-4'-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
AID57201Inhibition of human DNA Topoisomerase II1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antitumor agents. 124. New 4 beta-substituted aniline derivatives of 6,7-O,O-demethylene-4'-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
AID91975Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from small-cell-lung cancer in test 3; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID92108Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 uman tumor cell lines derived from Melanoma in test 6; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID92112Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from Renal cancer in test 8; log10 TGI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID91978Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from Ovarian cancer in test 7; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID96390In vitro cytotoxicity against KB cells after a 3-day incubation.1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID92106Tested for in vitro inhibitory activity against drug concentration causing 50% cell death inhibition in 56 human tumor cell lines derived from leukemia in test 9; log10 LC501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID96351Concentration required for 50% reduction in KB cell number after 3-day incubation1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antitumor agents. 124. New 4 beta-substituted aniline derivatives of 6,7-O,O-demethylene-4'-O-demethylpodophyllotoxin and related compounds as potent inhibitors of human DNA topoisomerase II.
AID92113Tested for in vitro inhibitory activity against drug concentration causing total cell growth inhibition in 56 human tumor cell lines derived from colon cancer in test 41994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID9638850% reduction in KB cell number after a 3-day incubation.1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID57200Evaluated for the inhibition of human DNA Topoisomerase II1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Antitumor agents. 123. Synthesis and human DNA topoisomerase II inhibitory activity of 2'-chloro derivatives of etoposide and 4 beta-(arylamino)-4'-O-demethylpodophyllotoxins.
AID53301Evaluated for inhibitory activity against DNA topoisomerase II1990Journal of medicinal chemistry, May, Volume: 33, Issue:5
Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID57061Percentage of intracellular covalent DNA-topoisomerase II complexes formed2002Journal of medicinal chemistry, May-23, Volume: 45, Issue:11
Antitumor agents. 213. Modeling of epipodophyllotoxin derivatives using variable selection k nearest neighbor QSAR method.
AID91972Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from leukemia in test 1; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID91974Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from renal cancer in test 8; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
AID52063% complex formation of cellular protein -DNA complex at a concentration of 10 uM1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Antitumor agents. 120. New 4-substituted benzylamine and benzyl ether derivatives of 4'-O-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II.
AID147562Tested for in vitro inhibitory activity against drug concentration causing 50% cell growth inhibition in 56 human tumor cell lines derived from Non-small-cell lung cancer in test 2; log10 GI501994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Antitumor agents. 152. In vitro inhibitory activity of etoposide derivative NPF against human tumor cell lines and a study of its conformation by X-ray crystallography, molecular modeling, and NMR spectroscopy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (69.23)18.2507
2000's3 (23.08)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]